RCKT Rocket Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RCKT

Price (delayed)

$23.7

Market cap

$2.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.92

Enterprise value

$2.11B

Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it ...

Highlights
Rocket Pharmaceuticals's EPS has increased by 10% YoY and by 8% from the previous quarter
RCKT's net income is down by 11% YoY but it is up by 2.8% from the previous quarter
The quick ratio has declined by 41% since the previous quarter and by 16% year-on-year
The debt is up by 10% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.rocketpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of RCKT
Market
Shares outstanding
90.5M
Market cap
$2.14B
Enterprise value
$2.11B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.34
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$243.72M
EBITDA
-$236.62M
Free cash flow
-$211.39M
Per share
EPS
-$2.92
Free cash flow per share
-$2.52
Book value per share
$5.46
Revenue per share
$0
TBVPS
$5.98
Balance sheet
Total assets
$566.34M
Total liabilities
$73.77M
Debt
$25.04M
Equity
$492.57M
Working capital
$329.72M
Liquidity
Debt to equity
0.05
Current ratio
7.8
Quick ratio
7.73
Net debt/EBITDA
0.14
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-45.9%
Return on equity
-51.8%
Return on invested capital
-67.8%
Return on capital employed
-47.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RCKT stock price

How has the Rocket Pharmaceuticals stock price performed over time
Intraday
4.08%
1 week
7.83%
1 month
-6.8%
1 year
33.45%
YTD
-20.92%
QTD
-12.03%

Financial performance

How have Rocket Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$259.66M
Net income
-$245.6M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 16% YoY but it has grown by 2.2% from the previous quarter
RCKT's net income is down by 11% YoY but it is up by 2.8% from the previous quarter

Growth

What is Rocket Pharmaceuticals's growth rate over time

Valuation

What is Rocket Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.34
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rocket Pharmaceuticals's EPS has increased by 10% YoY and by 8% from the previous quarter
The stock's price to book (P/B) is 10% more than its 5-year quarterly average of 3.8 and 7% more than its last 4 quarters average of 3.9
The equity has declined by 9% since the previous quarter

Efficiency

How efficient is Rocket Pharmaceuticals business performance
The ROIC has grown by 22% YoY and by 9% from the previous quarter
The return on assets is up by 3.8% year-on-year and by 3.4% since the previous quarter
RCKT's ROE is up by 3% from the previous quarter and by 3% YoY

Dividends

What is RCKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RCKT.

Financial health

How did Rocket Pharmaceuticals financials performed over time
Rocket Pharmaceuticals's current ratio has decreased by 42% QoQ and by 16% YoY
The quick ratio has declined by 41% since the previous quarter and by 16% year-on-year
The debt is 95% smaller than the equity
The debt is up by 10% year-on-year
The equity has declined by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.